
Collegium Pharmaceutical (COLL) Stock Forecast & Price Target
Collegium Pharmaceutical (COLL) Analyst Ratings
Bulls say
Collegium Pharmaceutical is poised for growth as they excel in the ADHD market and have a strong track record of successful mergers and acquisitions. With a focus on responsible pain management and a strong management team, the current stock price presents a potential investment opportunity. However, competition and market uncertainties make it difficult to have a fully positive outlook, leading to a Neutral rating and adjusted price target.
Bears say
Collegium Pharmaceutical is facing significant headwinds in its Pain franchise, with a looming revenue cliff in 2027 due to potential generic entry of Belbuca and Nucynta. The company's reliance on the continued success of its products in a highly competitive market, coupled with limited inorganic growth opportunities, presents risks to its long-term growth prospects. Furthermore, while the company has measures in place to mitigate the impact of potential generic competition, there is still uncertainty as to when and how this competition will manifest.
This aggregate rating is based on analysts' research of Collegium Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.
Collegium Pharmaceutical (COLL) Analyst Forecast & Price Prediction
Start investing in Collegium Pharmaceutical (COLL)
Order type
Buy in
Order amount
Est. shares
0 shares